Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
| Revenue (TTM) | $13.73M |
| Gross Profit (TTM) | $-113.92M |
| EBITDA | $-155.00M |
| Operating Margin | -916.00% |
| Return on Equity | -11.70% |
| Return on Assets | -9.44% |
| Revenue/Share (TTM) | $0.22 |
| Book Value | $15.47 |
| Price-to-Book | 1.01 |
| Price-to-Sales (TTM) | 71.72 |
| EV/Revenue | 0.938 |
| EV/EBITDA | -33.80 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 2178.00% |
| Shares Outstanding | $60.98M |
| Float | $39.13M |
| % Insiders | 1.69% |
| % Institutions | 102.73% |
Volatility is currently expanding
The mean of analysts' price targets for Janux Therapeutics (JANX) points to a 155.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Janux Therapeutics advances multiple oncology and immune therapy programs with key clinical updates, new studies and expanded partnerships with BMY and MRK.
The consensus price target hints at an 180.4% upside potential for Janux Therapeutics (JANX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The Undercovered Dozen series spotlights 12 lesser-covered stocks from the past week on Seeking Alpha. This week's edition covers articles published between April 24 and April 30, offering fresh investment ideas. The focus is on stocks that may offer unique opportunities due to limited analyst coverage.
SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that it will discontinue further clinical development of JANX008, its EGFR-targeted Tumor Activated T Cell Engager (TRACTr) program. Following completion of the Phase 1a portion of the study, which included dose escalation and expansion cohorts across multiple solid tumor indications, and an internal revie.
